Melanie L. Bailey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melanie L. Bailey has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- David A. Solomon
Department of Pathology, Stanford University School of Medicine, Stanford
8 shared publications - Derek M. van Pel8 shared publications
- Nigel J. O'NEil
The University of British Columbia Michael Smith Laboratories
8 shared publications - Philip Hieter
The University of British Columbia Michael Smith Laboratories
8 shared publications - Todd Waldman
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, District of Columbia, USA
8 shared publications Cliff Taggart
Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK
1 shared publication
Latest Publications
- Open Access
Inhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS)
SARS-CoV-2 binds to ACE2 receptors and enters cells. The symptoms are cough, breathlessness, loss of taste/smell and X-ray evidence of infiltrates on chest imaging initially caused by oedema, and subsequently by a lymphocytic pneumonitis. Coagulopathy, thrombosis and hypotension occur. Worse disease occurs with age, obesity, ischaemic heart disease, hypertension and diabetes. These features may be due to abnormal activation of the contact system. This triggers coagulation and the kallikrein-kinin system, leading to accumulation of bradykinin and its derivatives, which act on receptors B1R and B2R. Receptor activation causes cough, hypotension, oedema and release of the cytokine interleukin-6 (IL-6) which recruits lymphocytes. These effects are core features seen in early SARS CoV-2 infection. Methods and analysis In this study, hypoxic patients with COVID-19 with symptom onset ≤7 days will be randomised to either a bradykinin inhibitor (icatibant) or placebo. Patients and investigators will be blinded. The primary outcome will be blood oxygenation, measured by arterial blood sampling. The secondary outcome will be cardiovascular status. Retinal imaging will be performed to assess vessel size. Blood samples will be taken for measurement of inflammatory analyses including IL-6. As a separate substudy, we will also take comparator blood inflammatory samples from a COVID-19-negative cohort. Ethics and dissemination The study has received the following approvals: West Midlands–Edgbaston Research Ethics Committee. Medicines and Healthcare products Regulatory Agency has issued a clinical trial authorisation. Belfast Health and Social Care Trust is the study sponsor. Results will be made available to participants upon request and findings will be presented and published. Trial registration number NCT05407597
Open AccessInhibition of bradykinin in SARS-CoV-2 infection: a randomised, double-blind trial of icatibant compared with placebo (ICASARS)
SARS-CoV-2 binds to ACE2 receptors and enters cells. The symptoms are cough, breathlessness, loss of taste/smell and X-ray evidence of infiltrates on chest imaging initially caused by oedema, and subsequently by a lymphocytic pneumonitis. Coagulopathy, thrombosis and hypotension occur. Worse disease occurs with age, obesity, ischaemic heart disease, hypertension and diabetes. These features may be due to abnormal activation of the contact system. This triggers coagulation and the kallikrein-kinin system, leading to accumulation of bradykinin and its derivatives, which act on receptors B1R and B2R. Receptor activation causes cough, hypotension, oedema and release of the cytokine interleukin-6 (IL-6) which recruits lymphocytes. These effects are core features seen in early SARS CoV-2 infection. Methods and analysis In this study, hypoxic patients with COVID-19 with symptom onset ≤7 days will be randomised to either a bradykinin inhibitor (icatibant) or placebo. Patients and investigators will be blinded. The primary outcome will be blood oxygenation, measured by arterial blood sampling. The secondary outcome will be cardiovascular status. Retinal imaging will be performed to assess vessel size. Blood samples will be taken for measurement of inflammatory analyses including IL-6. As a separate substudy, we will also take comparator blood inflammatory samples from a COVID-19-negative cohort. Ethics and dissemination The study has received the following approvals: West Midlands–Edgbaston Research Ethics Committee. Medicines and Healthcare products Regulatory Agency has issued a clinical trial authorisation. Belfast Health and Social Care Trust is the study sponsor. Results will be made available to participants upon request and findings will be presented and published. Trial registration number NCT05407597
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
PDF file - 157K, Supp. Fig. 6- Incidence of A) micronuclei (MN), B) chromatin bridges (CB) and C) fragmented nuclei (FN) and in 42MGBA cell lines either untreated or treated with olaparib for four days. Graphs represent cell counts from three independent experiments. D) Presence of 53BP1 foci in paired 42MGBA cell lines untreated and treated with olaparib for four days. Error bars in D) are 95% confidence intervals.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
PDF file - 157K, Supp. Fig. 6- Incidence of A) micronuclei (MN), B) chromatin bridges (CB) and C) fragmented nuclei (FN) and in 42MGBA cell lines either untreated or treated with olaparib for four days. Graphs represent cell counts from three independent experiments. D) Presence of 53BP1 foci in paired 42MGBA cell lines untreated and treated with olaparib for four days. Error bars in D) are 95% confidence intervals.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
PDF file - 56K, Supp. Fig. 3- A) Propidium iodide-stained flow cytometry profiles of 42MGBA cell lines untreated and treated with olaparib. B) Cell cycle distribution of 42MGBA cell populations from three independent experiments.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
PDF file - 56K, Supp. Fig. 3- A) Propidium iodide-stained flow cytometry profiles of 42MGBA cell lines untreated and treated with olaparib. B) Cell cycle distribution of 42MGBA cell populations from three independent experiments.